| 2025-09-09 | 安蒸量 | 688581 | 74.94 | 机构专用 749.4 10 | 东方证券股份有限 AND INCREASE OF COLOR COLLECTION | Ka | | --- | --- | --- | --- | --- | --- | --- | | 交易日期 证券简称 | | 证券代码 | | 成交价(元) 成交宜额(万元) 成交量(*) 买入营业部 | 奥出营业那 公司杭州龙井路证 | 是否为专场 | 9月9日，安杰思大宗交易成交10万股，成交额749.4万元，占当日总成交额的7.6%，成交价74.94元，较 市场收盘价75.54元折价0.79%。 ...

投资者可于 2025 年 09 月 10 日（星期三）至 09 月 16 日（星期二）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IR@bioags.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688581 证券简称：安杰思 公告编号：2025-049 杭州安杰思医学科技股份有限公司 关于参加 2025 年半年度科创板医疗器械及医疗设备 行业集体业绩说明会的公告 杭州安杰思医学科技股份有限公司（以下简称"公司"）已于 2025 年 08 月 08 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 09 月 17 日（星期三） 15：00-17：00 参加由上海证券交易所主办的 2025 年半年度科创板医疗器械及医 疗设备行业集体业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动 ...

Summary of Key Points Core Viewpoint - Anjie Technology experienced a significant block trade on September 8, with a transaction volume of 100,000 shares and a transaction value of 7.723 million yuan, indicating a discount of 0.80% compared to the closing price of the day [2]. Trading Activity - The block trade was executed at a price of 77.23 yuan per share, with the buying side being an institutional proprietary account and the selling side being Dongfang Securities Co., Ltd. Hangzhou Longjing Road Securities Office [2]. - Over the past three months, Anjie Technology has recorded a total of 7 block trades, with a cumulative transaction value of 55.5267 million yuan [2]. Stock Performance - On the same day, Anjie Technology's closing price was 77.85 yuan, reflecting an increase of 6.54%, with a daily turnover rate of 5.25% and a total transaction amount of 166 million yuan [2]. - The net inflow of main funds for the day was 9.354 million yuan, and over the past five days, the stock has increased by 3.39% with a total net inflow of 9.0113 million yuan [2]. Margin Trading Data - The latest margin financing balance for Anjie Technology is 120 million yuan, which has decreased by 6.458 million yuan over the past five days, representing a decline of 5.12% [2].

Group 1 - The core transaction involved Anjisi, with a total of 100,000 shares traded on September 8, amounting to 7.723 million yuan, which represented 4.44% of the total trading volume for that day [1] - The transaction price was 77.23 yuan per share, reflecting a discount of 0.8% compared to the market closing price of 77.85 yuan [1]

Summary of Key Points Core Viewpoint - Anjie Technology executed a block trade on September 5, with a transaction amount of 7.249 million yuan and a trading price of 72.49 yuan, reflecting a discount of 0.79% compared to the closing price of the day [1] Trading Activity - The block trade involved a volume of 100,000 shares and was conducted by an institutional special seat as the buyer, while the seller was Dongfang Securities Co., Ltd. Hangzhou Longjing Road Securities Business Department [1] - Over the past three months, Anjie Technology has recorded a total of six block trades, amounting to 47.8037 million yuan [1] Market Performance - On the same day, Anjie Technology's closing price was 73.07 yuan, showing an increase of 0.98%, with a daily turnover rate of 1.97% and a total transaction amount of 59.3693 million yuan [1] - The net inflow of main funds for the day was 213,700 yuan, while the stock has seen a cumulative decline of 3.72% over the past five days, with a total net outflow of 8.7104 million yuan [1] Margin Trading Data - The latest margin financing balance for Anjie Technology stands at 118 million yuan, having decreased by 24.3029 million yuan over the past five days, representing a decline of 17.05% [1]

Core Insights - Anjie Si's stock closed at 73.07 CNY on September 5, with a rise of 0.98% [1] - A block trade occurred involving 100,000 shares, totaling 7.249 million CNY, with a price of 72.49 CNY per share and a premium rate of -0.79% [1] - The buyer was an institutional special account, while the seller was Dongfang Securities Co., Ltd. Hangzhou Longjing Road Securities Business Department [1] Trading Activity - In the last three months, Anjie Si has recorded six block trades, with a total transaction value of 47.8037 million CNY [1] - Over the past five trading days, the stock has declined by 3.72%, with a net outflow of 17.1701 million CNY from main funds [1]

Group 1 - On September 5, a block trade of 100,000 shares of Anjisi was executed, with a transaction amount of 7.249 million yuan, accounting for 10.88% of the total transaction volume for the day [1] - The transaction price was 72.49 yuan, which represents a discount of 0.79% compared to the market closing price of 73.07 yuan [1]

Financial Performance - In the first half of 2025, the company achieved operating revenue of 302 million yuan, a year-on-year increase of 14.56% [1] - The net profit attributable to shareholders was 126 million yuan, a year-on-year increase of 1.26% [1] - The net profit excluding non-recurring items was 112 million yuan, a year-on-year decrease of 7.06%, primarily due to financial expenses [1] - In Q2 2025, the company reported operating revenue of 174 million yuan, a year-on-year increase of 14.03% [1] - The net profit attributable to shareholders in Q2 was 70 million yuan, a year-on-year decrease of 2.65% [1] Revenue Growth - Domestic revenue grew by 10.50% year-on-year, while overseas revenue increased by 18.29% [2] - European revenue saw a significant increase of 38.28%, Asian revenue grew by 29.05%, and South American revenue surged by 58.95% [2] - North American revenue declined by 9.89% due to the impact of US tariffs [2] Business Optimization and R&D - The company follows a "sales generation, R&D generation, exploration generation" strategy to optimize existing products and explore new pipelines [3] - Innovations include a redesigned hemostatic clip in the GI field and a comprehensive ESD solution combining various treatment systems [3] - The company is advancing multiple R&D pipelines, including reusable flexible endoscopes and AI-based clinical diagnostic products [3] Financial Metrics - The overall gross margin in the first half of 2025 decreased by 1.34 percentage points to 70.21% [4] - The financial expense ratio increased significantly by 10.52 percentage points, influenced by increased financial management activities [4] - In Q2 2025, the comprehensive gross margin was 69.86%, with notable changes in various expense ratios [4] Profit Forecast - Projected operating revenues for 2025-2027 are 779 million, 978 million, and 1.198 billion yuan, with year-on-year growth rates of 22.36%, 25.55%, and 22.49% respectively [5] - Expected net profits for the same period are 315 million, 384 million, and 476 million yuan, with growth rates of 7.27%, 21.90%, and 24.10% respectively [5] - The current stock price corresponds to a PE ratio of 20, 17, and 13 for 2025-2027 [5]

Core Points - The stock price of Anjiasi (688581) closed at 75.89 yuan, down 9.21% from last week [1] - The company's market capitalization is currently 6.145 billion yuan, ranking 59th out of 126 in the medical device sector and 2814th out of 5152 in the A-share market [1] Company Performance - In the first half of 2025, the company's operating revenue increased by 14.56% year-on-year [2] - The total profit rose by 2.78% year-on-year, while the net profit attributable to shareholders increased by 1.26% year-on-year [1][2] - The net cash flow from operating activities decreased by 34.90% year-on-year [2] Research and Development - R&D investment grew by 33.29% year-on-year, with its proportion of operating revenue increasing by 1.60 percentage points [2] Compliance and Oversight - During the continuous supervision period, no major issues or violations were found [2]

Core Viewpoint - The report outlines the ongoing supervision and assessment of Hangzhou Anjisi Medical Technology Co., Ltd. by CITIC Securities, focusing on the company's compliance, financial performance, and potential risks in the medical device industry [1][2]. Group 1: Continuous Supervision Overview - CITIC Securities conducted a site inspection on July 14, 2025, as part of its ongoing supervisory responsibilities [1]. - The supervision included reviewing corporate governance documents, financial management systems, and fundraising management practices [1]. Group 2: Identified Issues and Rectification - No major issues were found during the supervision period, indicating effective management practices [2]. - The company faces core competitiveness risks due to the lengthy and complex nature of developing minimally invasive endoscopic devices [2][3]. Group 3: Major Risk Factors - The company is exposed to operational risks from increasing competition in the domestic market and potential price reductions due to healthcare cost control measures [2][4]. - Quality control is critical, as any product defects could harm the company's reputation and financial performance [3][4]. Group 4: Financial Performance - For the first half of 2025, the company reported a revenue of 302.43 million yuan, a 14.56% increase from the previous year [11]. - The total profit for the same period was 149.13 million yuan, reflecting a 2.78% increase [11]. - The net profit attributable to shareholders was 111.51 million yuan, showing a decrease of 7.06% when excluding non-recurring gains [11]. Group 5: Research and Development - The company has increased its R&D investment, with total R&D expenses reaching 34.46 million yuan, a 33.29% increase compared to the previous period [18]. - R&D efforts focus on innovative diagnostic and therapeutic devices, with a strong emphasis on integrating AI technologies [12][18]. Group 6: Market Dynamics - The company is expanding its market presence, with significant sales growth in Europe (38.28%) and Asia (29.05%), while facing a decline in North America (9.89%) due to trade tensions [16]. - The company actively adapts to new procurement policies and payment regulations in the healthcare sector to maintain competitiveness [8][9]. Group 7: Compliance and Governance - The company adheres to various international and domestic quality management standards, ensuring compliance in its operations [13]. - There were no significant violations of fundraising regulations during the supervision period, indicating sound financial governance [21][24].